ABP 494 (cetuximab biosimilar) / AbbVie, Amgen - LARVOL DELTA

Treatment approaches for BRAF V600E mutant metastatic colorectal cancer (YouTube) - "Chiara Cremolini, MD, PhD...highlights current treatment strategies for metastatic colorectal cancer. For patients with BRAF V600E mutations, treatment varies by mismatch repair (MMR) status. For proficient MMR (pMMR) tumors, the BEACON CRC trial (NCT02928224) supports using encorafenib plus cetuximab, with other ongoing trials evaluating nivolumab. For deficient MMR (dMMR) tumors, the SEAMARK trial (NCT05217446) shows promising results for pembrolizumab combined with encorafenib and cetuximab. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany."

Interview • Video

Expert Point of View: Pasi A. Jänne, MD, PhD, and Charu Aggarwal, MD, MPH (THE ASCO POST) - "The invited discussant of CodeBreak 100 was Pasi A. Jnne, MD, PhD...Charu Aggarwal, MD, MPH...commented on CodeBreak 100 for The ASCO Post....'This is likely related to the heterogeneity of the mutational landscape of KRAS G12C cancers.' Dr. Jnne added other possibilities - including the heavy pretreatment of the trial populations; patients' heavy smoking history; and that by binding to GDP, the drugs leave tumors vulnerable to upstream stimuli that could facilitate resistance."

Media quote